论文部分内容阅读
非小细胞肺癌 (NSCL C)在世界各地的发病率逐年上升 ,由于患者就诊时 80 %～ 90 %的病例已有转移 ,因此化疗是不可缺少的治疗手段。随着一些新药的问世 ,明显提高了 NSCL C的疗效。本文综述了各期非小细胞肺癌的治疗新进展
The incidence of non-small cell lung cancer (NSCL C) has been increasing year by year. Since 80% to 90% of cases have been metastasized during treatment, chemotherapy is an indispensable treatment. With the advent of some new drugs, the efficacy of NSCL C has been significantly improved. This article reviews recent advances in the treatment of non-small cell lung cancer